Neuralstem in the News
Neurogenic Drug Improves Depression in Small Trial
Science Editor Cynthia Fox issued a report on first-in-class neurogenic NSI-189/major depressive disorder (MDD) Phase I data, presented by Mass Gen/Harvard’s Dr. Marlene Freeman, at ASCP’s annual meeting. She reports that “depressed patients taking two different doses of the drug have now experienced a ‘clinically meaningful’ relief of depressive and cognitive symptoms across all measures in comparison to placebo. This relief continued throughout the follow-up period,” which was for two months following the 28-day dosing. Neuralstem’s President and CEO, Richard Garr, is quoted as saying, “this is a very solid sign pointing to confirming our thesis that what we see in animals—structurally rebuilding the hippocampus—is also happening in humans.”
ALS Breakthrough Involves Rhode Island Patient
NSI-566/ALS Phase II patient on Rhode Island ABC Channel 6 Report.
Neuralstem could seek partner for Phase II depression small molecule; to develop stem cell therapy solo – CEO
Neuralstem’s President and CEO discusses neurogenic small molecule lead compound, NSI-189, commercialization strategy with global life sciences business intelligence group, BioPharm Insight. Garr notes a partnership commitment would require the full potential of NSI-189 as a neurogenic agent in all potential indications on a global basis. The company plans to file an IND in late summer or early 3Q14 to commence the NSI-189 Phase II clinical trial in major depressive disorder before year-end, with Dr. Maurizio Fava, professor of Psychiatry, Harvard Medical School, cited as likely to be the principal investigator.
New trial may be step forward for spinal cord injuries
CNN Medical Managing Editor, Miriam Falco, reports on the promise of NSI-566 for chronic spinal cord injury, approved to commence a Phase I trial at the University of California, San Diego, School of Medicine. July is cited as the potential first treatment date by Neuralstem’s CSO Karl Johe, PhD. In the article, Dr. Johe and President and CEO Richard Garr give insights on the ability of NSI-566 to "actually build new circuitry” and “jump the gap with the new circuitry we've built.”
Neuralstem doses ischemic stroke patient with stem cells directly into the brain
“It is a crucial step forward for the company and the field at large, since optimizing cell therapy treatment for CNS indications will require delivering cells to the brain, as well as to the spinal cord.” - Neuralstem's Chairman and CSO, Karl Johe, PhD, quoted in BioWorld's article on the ongoing NSI-566/ischemic stroke trial in Beijing.
Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.